Article

FDA requires further study for oral voclosporin

The FDA has issued a complete response letter regarding a new drug application (NDA) for oral voclosporin (Luveniq, Lux Biosciences) for the treatment of non-infectious uveitis, according to the company.

Jersey City, NJ-The FDA has issued a complete response letter regarding a new drug application (NDA) for oral voclosporin (Luveniq, Lux Biosciences) for the treatment of non-infectious uveitis, according to the company.

The FDA issues such a letter when it has reviewed a file but has questions that preclude the approval of the NDA in its current form. Lux Biosciences and its partner, Isotechnika Pharma, are evaluating the letter but indicate that the agency said that it regards the data from one of the two pivotal studies submitted in the NDA as positive. Officials at Lux Biosciences said the company plans to begin an additional pivotal trial of oral voclosporin before the end of the year.

“We continue to work with FDA to address [its] outstanding questions regarding the safety and efficacy of [oral voclosporin], and the Lux Biosciences’ Board of Directors is supportive of our starting the additional trial,” said Dean Mitchell, Lux Biosciences’ president and chief executive officer. “At the same time, the European Medicines Agency review of the marketing authorization application [MAA] for [oral voclosporin] remains on course for completion in the first quarter of 2011.”

The company announced submission of the NDA and MAA for oral voclosporin Feb. 3.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.